Pegylated IFN-α2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV

被引:5
作者
Mallolas, Josep [1 ]
Laguno, Montserrat [1 ]
机构
[1] Hosp Clin Barcelona, Serv Enfermedades Infecciosas, Barcelona, Spain
关键词
antiviral agent; chronic hepatitis C; early virological response; HIV/HCV coinfection; HIV infection; IFN-alpha(2b); improved adherence; negative predictive value; positive predictive value; rapid virological response; relapse rate; ribavirin; sustained virological response; viral load; weight based;
D O I
10.1586/14787210.6.3.281
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Since 1995, after the generalization of highly active antiretroviral therapy (HAART), HCV coinfection in patients with HIV has become a clinical problem of first magnitude. In fact, currently, HCV coinfection is the primary cause of morbi-mortality of AIDS patients in many hospitals. As a consequence, a significant number of clinical trials have been carried out during the past 8-10 years on HCV/HIV-coinfected patients, and have been coincident that the use of pegylated interferon (PEG-IFN) plus ribavirin should be now the gold standard for treating these patients. Various prospective, randomized studies have reached the conclusion that PEG-IFN-alpha(2b) plus ribavirin achieves HCV cure rates in approximately 50% of all patients, together with important clinical consequences, since hepatic illness progression stops or even reverts. Although adverse events are extremely common with this combined treatment, it is also true that their handling by experts means that only 10-15% of patients must abandon treatment.
引用
收藏
页码:281 / 289
页数:9
相关论文
共 51 条
[1]  
Ahn Joseph, 2004, Expert Rev Anti Infect Ther, V2, P17, DOI 10.1586/14787210.2.1.17
[2]   Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].
Alberti, A ;
Clumeck, N ;
Collins, S ;
Gerlich, W ;
Lundgren, J ;
Palù, G ;
Reiss, P ;
Thiebaut, R ;
Weiland, O ;
Yazdanpanah, Y ;
Zeuzem, S .
JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624
[3]   Epidemiology of viral hepatitis and HIV co-infection [J].
Alter, MJ .
JOURNAL OF HEPATOLOGY, 2006, 44 :S6-S9
[4]  
[Anonymous], 1999, J Hepatol, V30, P956
[5]   Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection:: indications for the investigation of new treatment approaches [J].
Ballesteros, AL ;
Franco, S ;
Fuster, D ;
Planas, R ;
Martínez, MA ;
Acosta, L ;
Sirera, G ;
Salas, A ;
Tor, J ;
Rey-Joly, C ;
Clotet, B ;
Tural, C .
AIDS, 2004, 18 (01) :59-66
[6]   Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination - Does abacavir play a role? [J].
Bani-Sadr, Firouze ;
Denoeud, Lise ;
Morand, Patrice ;
Lunel-Fabiani, Francoise ;
Pol, Stanislas ;
Cacoub, Patrice ;
Perronne, Christian ;
Carrat, Fabrice .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) :123-125
[7]   Pharmacokinetics of pegylated interferons: What is misleading? [J].
Caliceti, P .
DIGESTIVE AND LIVER DISEASE, 2004, 36 :S334-S339
[8]  
Cargnel A, 2005, ANTIVIR THER, V10, P309
[9]   Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].
Carrat, F ;
Bani-Sadr, F ;
Pol, S ;
Rosenthal, E ;
Lunel-Fabiani, F ;
Benzekri, A ;
Morand, P ;
Goujard, C ;
Pialoux, G ;
Piroth, L ;
Salmon-Céron, D ;
Degott, C ;
Cacoub, P ;
Perronne, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848
[10]   Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients [J].
Crespo, M. ;
Sauleda, S. ;
Esteban, J. I. ;
Juarez, A. ;
Ribera, E. ;
Andreu, A. L. ;
Falco, V. ;
Quer, J. ;
Ocana, I. ;
Ruiz, I. ;
Buti, M. ;
Pahissa, A. ;
Esteban, R. ;
Guardia, J. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (04) :228-238